Antibody-based immunosuppressive agents for corneal transplantation

Area of Science:

• Immunology
• Biotechnology
• Ophthalmology

Background:

• Antibody engineering has advanced significantly over the past 20 years.
• Novel antibody-based drugs and constructs, including small antibody fragments for topical administration, have been developed.
• Therapeutic antibody constructs and fragments have driven clinical progress in rheumatology, oncology, transplantation medicine, and ophthalmology.

Purpose of the Study:

• To review engineered antibody-based therapeutic agents.
• To summarize the current use of these agents in transplantation medicine.
• To highlight their specific application and limited use in corneal transplantation.

Main Methods:

• Literature review of antibody engineering advancements.
• Analysis of therapeutic antibody applications in solid organ transplantation.
• Examination of existing reports on antibody use in corneal transplantation.

Main Results:

• Antibody-based therapies are established immunosuppressants in solid organ transplantation.
• There is limited published data on the use of antibody-based therapies in corneal transplantation.
• Engineered antibody fragments offer potential for topical administration.

Conclusions:

• Engineered antibodies represent a promising therapeutic class.
• Their application in corneal transplantation requires further investigation.
• Current use in corneal transplantation is minimal but holds future potential.